Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Charles Kirkpatrick

Allergy & Immunology Aurora, CO Medical Doctor

NPI 1013007780 CMS profile 317917

12605 E 16Th Ave, Ste B164, Aurora, CO 80045

Open in the dashboard

General payments

$6,903

15 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Charles Kirkpatrick of Aurora, CO is reported in the CMS Open Payments database as having received $6,903 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $214 2
2021 General $1,200 1
2020 General $3,000 1
2019 General $2,489 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Kirkpatrick
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Charles Kirkpatrick were reported at $0. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Charles Kirkpatrick Allergy & Immunology median Middle half National median
2019 $2,489 $378 $115–$1,178 $163
2020 $3,000 $303 $75–$1,581 $114
2021 $1,200 $407 $122–$1,475 $132
2022 $0 $357 $120–$1,340 $149
2023 $214 $445 $124–$1,536 $160
2024 $0 $541 $129–$1,763 $164
2025 $0 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Pharming Healthcare, Inc. $3,000 1 payment
  2. BioCryst Pharmaceuticals, Inc. $2,326 6 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,200 1 payment
  4. Shire North American Group Inc $126 3 payments
  5. AstraZeneca Pharmaceuticals LP $121 1 payment
  6. Genentech USA, Inc. $93 1 payment
  7. CSL Behring $37 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Honoraria $5,125 3 payments
  2. Consulting Fee $1,200 1 payment
  3. Food and Beverage $517 9 payments
  4. Travel and Lodging $49 1 payment
  5. Education $12 1 payment
Products named General payments · program years 2019–2023
  1. RUCONEST $3,000 1 payment
  2. GAMMAGARD LIQUID $1,200 1 payment
  3. TEZSPIRE $121 1 payment
  4. Xolair $93 1 payment
  5. CINRYZE $73 1 payment
  6. Haegarda $37 2 payments
  7. TAKHZYRO $28 1 payment
  8. HYQVIA $25 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Allergy/ Immunology: 449

Drug cost

$563,929

Median for Allergy/ Immunology: $169,700

Branded share of claims

100%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ilaris Canakinumab/Pf Brand 13 $563,929

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$1,794

Medicare's payments for the services billed

Medicare patients

14

Average age 63

Services billed

22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record